CoChat

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

Open access
Compte, Marta, Harwood, Seandean Lykke, Muñoz, Ines G., Navarro, Rocio, Zonca, Manuela, Perez-Chacon, Gema, Erce-Llamazares, Ainhoa, Merino, Nekane, Tapia-Galisteo, Antonio, Cuesta, Angel M., Mikkelsen, Kasper, Caleiras, Eduardo, Nuñez-Prado, Natalia, Aznar, M. Angela, Lykkemark, Simon, Martínez-Torrecuadrada, Jorge, Melero, Ignacio, Blanco, Francisco J., Bernardino de la Serna, Jorge, Zapata, Juan M., Sanz, Laura, Alvarez-Vallina, Luis · 2018 · Nature Communications
Cited by 142

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

The costimulation of immune cells using first-generation anti-4-1BB monoclonal antibodies (mAbs) has demonstrated anti-tumor activity in human trials. Further clinical development, however, is restricted by significant off-tumor toxicities associated with FcγR interactions. Here, we have designed an Fc-free tumor-targeted 4-1BB-agonistic trimerbody, 1D8 N/C EGa1, consisting of three anti-4-1BB single-chain variable fragments and three anti-EGFR single-domain antibodies positioned in an extended hexagonal conformation around the collagen XVIII homotrimerization domain. The1D8 N/C EGa1 trimerbody demonstrated high-avidity binding to 4-1BB and EGFR and a potent in vitro costimulatory capacity in the presence of EGFR. The trimerbody rapidly accumulates in EGFR-positive tumors and exhibits anti-tumor activity similar to IgG-based 4-1BB-agonistic mAbs. Importantly, treatment with 1D8 N/C EGa1 does not induce systemic inflammatory cytokine production or hepatotoxicity associated with IgG-based 4-1BB agonists. These results implicate FcγR interactions in the 4-1BB-agonist-associated immune abnormalities, and promote the use of the non-canonical antibody presented in this work for safe and effective costimulatory strategies in cancer immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-07195-w

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 6 references

Cited by

See all 142

Metadata

Authors
Compte, M., Harwood, S. L., Muñoz, I. G., Navarro, R., Zonca, M., Perez-Chacon, G., Erce-Llamazares, A., Merino, N., Tapia-Galisteo, A., Cuesta, A. M., Mikkelsen, K., Caleiras, E., Nuñez-Prado, N., Aznar, M. A., Lykkemark, S., Martínez-Torrecuadrada, J., Melero, I., Blanco, F. J., Bernardino de la Serna, J., Zapata, J. M., Sanz, L., & Alvarez-Vallina, L.
Venue
Nature Communications
Published
2018-11-15
Volume
9
Issue
1
Pages
4809-4809
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2900183473
Cited by
142
References
6
FWCI
9.76
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. https://app.cochat.ai/papers/10.1038/s41467-018-07195-w
The paper
Compte, M., Harwood, S. L., Muñoz, I. G., Navarro, R., Zonca, M., Perez-Chacon, G., Erce-Llamazares, A., Merino, N., Tapia-Galisteo, A., Cuesta, A. M., Mikkelsen, K., Caleiras, E., Nuñez-Prado, N., Aznar, M. A., Lykkemark, S., Martínez-Torrecuadrada, J., Melero, I., Blanco, F. J., Bernardino de la Serna, J., . . . Alvarez-Vallina, L. (2018). A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. Nature Communications. https://doi.org/10.1038/s41467-018-07195-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.